NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization615.92 mln
Float83.51 mln
Earnings Date05/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.97
Likely reliable
1-Year Forecast
8.38
Transformational upside
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-49.59
Deeply negative
Business Description
Aclaris Therapeutics is a US-based clinical-stage biopharmaceutical company focused on developing new treatments for immune and inflammatory diseases. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is advancing several drug candidates targeting conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, and other respiratory and autoimmune disorders. Its pipeline spans multiple stages of clinical testing, with therapies designed to work through a range of biological mechanisms that regulate immune cell activity.
